Lupin is currently trading at Rs. 1479.50, up by 10.05 points or 0.68% from its previous closing of Rs. 1469.45 on the BSE.
The scrip opened at Rs. 1474.70 and has touched a high and low of Rs. 1482.40 and Rs. 1472.60 respectively. So far 54,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1874.30 on 14-Mar-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1482.40 and Rs. 1450.00 respectively. The current market cap of the company is Rs. 66,812.00 crore.
The promoters holding in the company stood at 46.71%, while Institutions and Non-Institutions held 41.46% and 11.83% respectively.
Lupin has launched its Clobetasol Propionate Topical Solution USP, 0.05% having received an approval from the United States Food and Drug Administration (USFDA) earlier to market a generic version of Fougera Pharmaceuticals’ Temovate (clobetasol propionate) Scalp Application, 0.05%.
Lupin’s Clobetasol Propionate Topical Solution USP, 0.05% is an AT rated generic equivalent of Fougera Pharmaceuticals’ Temovate (clobetasol propionate) Scalp Application, 0.05%. It is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. Temovate Clobetasol Propionate Scalp Application had US sales of $64.1 million as per IMS MAT December 2016.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.